{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,16]],"date-time":"2024-08-16T07:07:58Z","timestamp":1723792078224},"reference-count":37,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,9,26]]},"DOI":"10.7759\/cureus.45989","type":"journal-article","created":{"date-parts":[[2023,9,26]],"date-time":"2023-09-26T12:50:07Z","timestamp":1695732607000},"source":"Crossref","is-referenced-by-count":1,"title":["Clinical and Immunological Impacts of Latent Toxoplasmosis on COVID-19 Patients"],"prefix":"10.7759","author":[{"given":"Samar","family":"Habib","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eman","family":"Hamza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Randa","family":"El-Gamal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nessma A","family":"Nosser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wafaa A","family":"Aboukamar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sherehan","family":"Abdelsalam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ali","family":"Sobh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamed","family":"Elegezy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamed","family":"Elbayoumy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Waleed","family":"Eldars","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Khaled","family":"Elmasry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marwa H","family":"Elnagdy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1007\/s00436-010-2013-9","article-title":"Modulation of immunity in mice with latent toxoplasmosis--the experimental support for the immunosuppression hypothesis of Toxoplasma-induced changes in reproduction of mice and humans","volume":"107","author":"Ka\u0148kov\u00e1 S","year":"2010","unstructured":"Ka\u0148kov\u00e1 S, Hol\u00e1\u0148 V, Zaj\u00edcov\u00e1 A, Kodym P, Flegr J. Modulation of immunity in mice with latent toxoplasmosis--the experimental support for the immunosuppression hypothesis of Toxoplasma-induced changes in reproduction of mice and humans. Parasitol Res. 2010, 107:1421-7. 10.1007\/s00436-010-2013-9","journal-title":"Parasitol Res"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(04)16412-X","article-title":"Toxoplasmosis","volume":"363","author":"Montoya JG","year":"2004","unstructured":"Montoya JG, Liesenfeld O. Toxoplasmosis. Lancet. 2004, 363:1965-76. 10.1016\/S0140-6736(04)16412-X","journal-title":"Lancet"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2021.01.007","article-title":"Adaptive immunity to SARS-CoV-2 and COVID-19","volume":"184","author":"Sette A","year":"2021","unstructured":"Sette A, Crotty S. Adaptive immunity to SARS-CoV-2 and COVID-19. Cell. 2021, 184:861-80. 10.1016\/j.cell.2021.01.007","journal-title":"Cell"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002550","article-title":"Immune profiling of COVID-19: preliminary findings and implications for the pandemic","volume":"9","author":"Maecker HT","year":"2021","unstructured":"Maecker HT. Immune profiling of COVID-19: preliminary findings and implications for the pandemic. J Immunother Cancer. 2021, 9:10.1136\/jitc-2021-002550","journal-title":"J Immunother Cancer"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2020.05.002","article-title":"Immunology of COVID-19: current state of the science","volume":"52","author":"Vabret N","year":"2020","unstructured":"Vabret N, Britton GJ, Gruber C, et al.. Immunology of COVID-19: current state of the science. Immunity. 2020, 52:910-41. 10.1016\/j.immuni.2020.05.002","journal-title":"Immunity"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2020.08.001","article-title":"Severe COVID-19 is marked by a dysregulated myeloid cell compartment","volume":"182","author":"Schulte-Schrepping J","year":"2020","unstructured":"Schulte-Schrepping J, Reusch N, Paclik D, et al.. Severe COVID-19 is marked by a dysregulated myeloid cell compartment. Cell. 2020, 182:1419-1440.e23. 10.1016\/j.cell.2020.08.001","journal-title":"Cell"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-020-0331-4","article-title":"Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages","volume":"20","author":"Merad M","year":"2020","unstructured":"Merad M, Martin JC. Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages. Nat Rev Immunol. 2020, 20:355-62. 10.1038\/s41577-020-0331-4","journal-title":"Nat Rev Immunol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1126\/science.abd4585","article-title":"Autoantibodies against type I IFNs in patients with life-threatening COVID-19","volume":"370","author":"Bastard P","year":"2020","unstructured":"Bastard P, Rosen LB, Zhang Q, et al.. Autoantibodies against type I IFNs in patients with life-threatening COVID-19. Science. 2020, 370:10.1126\/science.abd4585","journal-title":"Science"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2020.08.017","article-title":"Robust T Cell immunity in convalescent individuals with asymptomatic or mild COVID-19","volume":"183","author":"Sekine T","year":"2020","unstructured":"Sekine T, Perez-Potti A, Rivera-Ballesteros O, et al.. Robust T Cell immunity in convalescent individuals with asymptomatic or mild COVID-19. Cell. 2020, 183:158-168.e14. 10.1016\/j.cell.2020.08.017","journal-title":"Cell"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-020-0782-6","article-title":"Broad and strong memory CD4(+) and CD8(+) T cells induced by SARS-CoV-2 in UK convalescent individuals following COVID-19","volume":"21","author":"Peng Y","year":"2020","unstructured":"Peng Y, Mentzer AJ, Liu G, et al.. Broad and strong memory CD4(+) and CD8(+) T cells induced by SARS-CoV-2 in UK convalescent individuals following COVID-19. Nat Immunol. 2020, 21:1336-45. 10.1038\/s41590-020-0782-6","journal-title":"Nat Immunol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1186\/s12964-022-00856-w","article-title":"A comprehensive review about immune responses and exhaustion during coronavirus disease (COVID-19)","volume":"20","author":"Mohammed RN","year":"2022","unstructured":"Mohammed RN, Tamjidifar R, Rahman HS, et al.. A comprehensive review about immune responses and exhaustion during coronavirus disease (COVID-19). Cell Commun Signal. 2022, 20:79. 10.1186\/s12964-022-00856-w","journal-title":"Cell Commun Signal"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.2001067","article-title":"Systematic examination of antigen-specific recall T Cell responses to SARS-CoV-2 versus influenza virus reveals a distinct inflammatory profile","volume":"206","author":"Law JC","year":"2021","unstructured":"Law JC, Koh WH, Budylowski P, et al.. Systematic examination of antigen-specific recall T Cell responses to SARS-CoV-2 versus influenza virus reveals a distinct inflammatory profile. J Immunol. 2021, 206:37-50. 10.4049\/jimmunol.2001067","journal-title":"J Immunol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1038\/nri3598","article-title":"Innate immunity to Toxoplasma gondii infection","volume":"14","author":"Yarovinsky F","year":"2014","unstructured":"Yarovinsky F. Innate immunity to Toxoplasma gondii infection. Nat Rev Immunol. 2014, 14:109-21. 10.1038\/nri3598","journal-title":"Nat Rev Immunol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.micinf.2007.09.004","article-title":"Control of IFN-gamma-mediated host resistance to intracellular pathogens by immunity-related GTPases (p47 GTPases)","volume":"9","author":"Taylor GA","year":"2007","unstructured":"Taylor GA, Feng CG, Sher A. Control of IFN-gamma-mediated host resistance to intracellular pathogens by immunity-related GTPases (p47 GTPases). Microbes Infect. 2007, 9:1644-51. 10.1016\/j.micinf.2007.09.004","journal-title":"Microbes Infect"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.157.5.2103","article-title":"IL-15 augments CD8+ T cell-mediated immunity against Toxoplasma gondii infection in mice","volume":"157","author":"Khan IA","year":"1996","unstructured":"Khan IA, Kasper LH. IL-15 augments CD8+ T cell-mediated immunity against Toxoplasma gondii infection in mice. J Immunol. 1996, 157:2103-8. 10.4049\/jimmunol.157.5.2103","journal-title":"J Immunol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1007\/s40588-019-0114-5","article-title":"Toxoplasma: immunity and pathogenesis","volume":"6","author":"Khan IA","year":"2019","unstructured":"Khan IA, Ouellette C, Chen K, Moretto M. Toxoplasma: immunity and pathogenesis. Curr Clin Microbiol Rep. 2019, 6:44-50. 10.1007\/s40588-019-0114-5","journal-title":"Curr Clin Microbiol Rep"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1038\/nrmicro2858","article-title":"Modulation of innate immunity by Toxoplasma gondii virulence effectors","volume":"10","author":"Hunter CA","year":"2012","unstructured":"Hunter CA, Sibley LD. Modulation of innate immunity by Toxoplasma gondii virulence effectors. Nat Rev Microbiol. 2012, 10:766-78. 10.1038\/nrmicro2858","journal-title":"Nat Rev Microbiol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1007\/s12275-017-7392-5","article-title":"Dense Granule Protein-7 (GRA-7) of Toxoplasma gondii inhibits viral replication in vitro and in vivo","volume":"55","author":"Weeratunga P","year":"2017","unstructured":"Weeratunga P, Herath TU, Kim TH, et al.. Dense Granule Protein-7 (GRA-7) of Toxoplasma gondii inhibits viral replication in vitro and in vivo. J Microbiol. 2017, 55:909-17. 10.1007\/s12275-017-7392-5","journal-title":"J Microbiol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1007\/s11686-022-00559-9","article-title":"Exploring the association between latent Toxoplasma gondii infection and COVID-19 in hospitalized patients: first registry-based study","volume":"67","author":"Montazeri M","year":"2022","unstructured":"Montazeri M, Nakhaei M, Fakhar M, et al.. Exploring the association between latent Toxoplasma gondii infection and COVID-19 in hospitalized patients: first registry-based study. Acta Parasitol. 2022, 67:1172-9. 10.1007\/s11686-022-00559-9","journal-title":"Acta Parasitol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2020.02.006","article-title":"Netrin-1: a new promising diagnostic marker for muscle invasion in bladder cancer","volume":"38","author":"El-Gamal R","year":"2020","unstructured":"El-Gamal R, Mokhtar N, Ali-El-Dein B, Baiomy AA, Aboazma SM. Netrin-1: a new promising diagnostic marker for muscle invasion in bladder cancer. Urol Oncol. 2020, 38:640.e1-640.e12. 10.1016\/j.urolonc.2020.02.006","journal-title":"Urol Oncol"},{"key":"ref21","unstructured":"Pick primers from a DNA sequence. (2022). Accessed. 07\/15\/2022: http:\/\/www.bioinformatics.nl\/cgi-bin\/primer3plus\/primer3plus.cgi."},{"key":"ref22","unstructured":"Primer-Blast. (2022). Accessed. 07\/15\/2022: https:\/\/www.ncbi.nlm.nih.gov\/tools\/primer-blast\/."},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1006\/meth.2001.1262","article-title":"Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method","volume":"25","author":"Livak KJ","year":"2001","unstructured":"Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001, 25:402-8. 10.1006\/meth.2001.1262","journal-title":"Methods"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0239802","article-title":"Clinical laboratory parameters associated with severe or critical novel coronavirus disease 2019 (COVID-19): a systematic review and meta-analysis","volume":"15","author":"Moutchia J","year":"2020","unstructured":"Moutchia J, Pokharel P, Kerri A, McGaw K, Uchai S, Nji M, Goodman M. Clinical laboratory parameters associated with severe or critical novel coronavirus disease 2019 (COVID-19): a systematic review and meta-analysis. PLoS One. 2020, 15:e0239802. 10.1371\/journal.pone.0239802","journal-title":"PLoS One"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.21608\/puj.2020.20986.1058","article-title":"Exposure to toxoplasmosis among the Egyptian population: A systematic review","volume":"13","author":"Taman A","year":"2020","unstructured":"Taman A, Alhusseiny S. Exposure to toxoplasmosis among the Egyptian population: A systematic review. Parasitologists United Journal. 2020, 13:1-10. 10.21608\/puj.2020.20986.1058","journal-title":"Parasitologists United Journal"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1007\/s00436-009-1350-z","article-title":"Seroprevalence of and risk factors for Toxoplasma gondii antibodies among asymptomatic blood donors in Egypt","volume":"104","author":"Elsheikha HM","year":"2009","unstructured":"Elsheikha HM, Azab MS, Abousamra NK, Rahbar MH, Elghannam DM, Raafat D. Seroprevalence of and risk factors for Toxoplasma gondii antibodies among asymptomatic blood donors in Egypt. Parasitol Res. 2009, 104:1471-6. 10.1007\/s00436-009-1350-z","journal-title":"Parasitol Res"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1016\/j.annemergmed.2008.06.339","article-title":"316: Toxoplasma gondii antibodies and associated oxidative stress among asymptomatic blood donors","volume":"52","author":"Abousamra NK","year":"2008","unstructured":"Abousamra NK. 316: Toxoplasma gondii antibodies and associated oxidative stress among asymptomatic blood donors. Annals of Emergency Medicine. 2008, 52:138. 10.1016\/j.annemergmed.2008.06.339","journal-title":"Annals of Emergency Medicine"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph17134809","article-title":"A review on the prevalence of Toxoplasma gondii in humans and animals reported in Malaysia from 2008-2018","volume":"17","author":"Nasiru Wana M","year":"2020","unstructured":"Nasiru Wana M, Mohd Moklas MA, Watanabe M, et al.. A review on the prevalence of Toxoplasma gondii in humans and animals reported in Malaysia from 2008-2018. Int J Environ Res Public Health. 2020, 17:10.3390\/ijerph17134809","journal-title":"Int J Environ Res Public Health"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2019.00235","article-title":"Long-term impact of Toxoplasma gondii infection on human monocytes","volume":"9","author":"Ehmen HG","year":"2019","unstructured":"Ehmen HG, L\u00fcder CG. Long-term impact of Toxoplasma gondii infection on human monocytes. Front Cell Infect Microbiol. 2019, 9:235. 10.3389\/fcimb.2019.00235","journal-title":"Front Cell Infect Microbiol"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1007\/s11356-021-17126-w","article-title":"Is COVID-19 associated with latent toxoplasmosis?","volume":"28","author":"Ghaffari S","year":"2021","unstructured":"Ghaffari S, Kalantari N, Gorgani-Firouzjaee T, Bayani M, Jalali F, Daroonkola MA. Is COVID-19 associated with latent toxoplasmosis?. Environ Sci Pollut Res Int. 2021, 28:67886-90. 10.1007\/s11356-021-17126-w","journal-title":"Environ Sci Pollut Res Int"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1007\/s12639-022-01556-5","article-title":"Toxoplasmosis and symptoms severity in patients with COVID-19 in referral centers in Northern Iran","volume":"47","author":"Geraili A","year":"2023","unstructured":"Geraili A, Badirzadeh A, Sadeghi M, et al.. Toxoplasmosis and symptoms severity in patients with COVID-19 in referral centers in Northern Iran. J Parasit Dis. 2023, 47:185-91. 10.1007\/s12639-022-01556-5","journal-title":"J Parasit Dis"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.3390\/life11090988","article-title":"Secreted effectors modulating immune responses to Toxoplasma gondii","volume":"11","author":"Tomita T","year":"2021","unstructured":"Tomita T, Guevara RB, Shah LM, Afrifa AY, Weiss LM.  Secreted effectors modulating immune responses to Toxoplasma gondii. Life (Basel). 2021, 11:10.3390\/life11090988","journal-title":"Life (Basel)"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1186\/s13071-021-05021-9","article-title":"Toxoplasmosis is a risk factor for acquiring SARS-CoV-2 infection and a severe course of COVID-19 in the Czech and Slovak population: a preregistered exploratory internet cross-sectional study","volume":"14","author":"Flegr J","year":"2021","unstructured":"Flegr J. Toxoplasmosis is a risk factor for acquiring SARS-CoV-2 infection and a severe course of COVID-19 in the Czech and Slovak population: a preregistered exploratory internet cross-sectional study. Parasit Vectors. 2021, 14:508. 10.1186\/s13071-021-05021-9","journal-title":"Parasit Vectors"},{"key":"ref34","article-title":"Toxoplasma gondii as a possible risk factor for COVID-19 severity: a case-control study","volume":"30","author":"Sharaf-El-Deen SA","year":"2021","unstructured":"Sharaf-El-Deen SA. Toxoplasma gondii as a possible risk factor for COVID-19 severity: a case-control study. Egyptian Journal of Medical Microbiology. 2021, 30:125-132.","journal-title":"Egyptian Journal of Medical Microbiology"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1002\/jnr.24917","article-title":"A role for T-cell exhaustion in Long COVID-19 and severe outcomes for several categories of COVID-19 patients","volume":"99","author":"Roe K","year":"2021","unstructured":"Roe K. A role for T-cell exhaustion in Long COVID-19 and severe outcomes for several categories of COVID-19 patients. J Neurosci Res. 2021, 99:2367-76. 10.1002\/jnr.24917","journal-title":"J Neurosci Res"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-69351-x","article-title":"A negative covariation between toxoplasmosis and CoVID-19 with alternative interpretations","volume":"10","author":"Jankowiak \u0141","year":"2020","unstructured":"Jankowiak \u0141, Rozsa L, Tryjanowski P, M\u00f8ller AP. A negative covariation between toxoplasmosis and CoVID-19 with alternative interpretations. Sci Rep. 2020, 10:12512. 10.1038\/s41598-020-69351-x","journal-title":"Sci Rep"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1186\/s13099-021-00427-3","article-title":"Role of interferon gamma in SARS-CoV-2-positive patients with parasitic infections","volume":"13","author":"Abdel-Hamed EF","year":"2021","unstructured":"Abdel-Hamed EF, Ibrahim MN, Mostafa NE, et al.. Role of interferon gamma in SARS-CoV-2-positive patients with parasitic infections. Gut Pathog. 2021, 13:29. 10.1186\/s13099-021-00427-3","journal-title":"Gut Pathog"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/189768-clinical-and-immunological-impacts-of-latent-toxoplasmosis-on-covid-19-patients","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T20:06:34Z","timestamp":1707509194000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/189768-clinical-and-immunological-impacts-of-latent-toxoplasmosis-on-covid-19-patients"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,26]]},"references-count":37,"URL":"https:\/\/doi.org\/10.7759\/cureus.45989","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9,26]]}}}